Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Volume: 89, Issue: 3, Pages: 701 - 711
Published: Mar 1, 2016
Abstract
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible...
Paper Details
Title
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Published Date
Mar 1, 2016
Volume
89
Issue
3
Pages
701 - 711
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.